Surprise Results For Urinary Tract Infections And Sexually Transmitted Diseases In African Trial
Trials in Ghana, Africa, on Malaria victims using a new recently patented advanced colloidal silver solution have had some useful side effects. Not only did the advanced silver solution clear up the malaria, but it also proved to be effective against Vaginitis, Urinary Tract Infections and Sexually Transmitted Diseases such as gonorrhea that the malaria patients were also suffering from.
The new advanced silver solution is produced by American Biotech Labs, who supplied about 1000 of the 8oz bottles of colloidal silver which were used in the trial conducted across 4 Ghanaian clinics/hospitals.
The Ghanaian human trials support many US laboratory trials conducted by a number of top university and research establishments. Although colloidal silver has been around for decades having originally been patented in 1924, this new advanced colloidal silver solution has been able to demonstrate new technology and capabilities. This culminated in a new patent in 2006, representing a major step forward.
Numerous claims are made for the 2006 patent by the manufacturer including that it exhibits antimicrobial properties against (amongst many others gonorrhea, urinary tract infections, vaginal infections, trichomonas vaginalis and Candida albicans. These claims have been independently accepted and validated by the US Patent Office.
In US laboratory trials it was established that due to the high potency of the new advanced colloidal silver, urinary tract and sexually transmitted diseases could be killed at extremely low concentrations of the silver suspension in water.
Urinary tract infections such as Pseudomonas Aeruginosa was killed at just 5.0 parts per million, whilst other urinary tract infections; Streptococcus Faecalis, E.Coli, Klebsiella Pneumoniae, Enterobacter Aerpyogenes were killed at just 2.5 parts per million.
Also, the yeast infection, Candida albicans and the vaginitis infection Trichomonas vaginalis were both killed at only 10.0 parts per million.
The advanced silver solution is commercially available at 14 parts per million, which is clearly strong enough for most requirements. Most other colloidal silvers have to be hundreds or even thousands of parts per million to even come close to achieving the same results.
About the Author: Trials results from Ghanaian human studies were used to support the American Biotech Labs application for the first colloidal silver patent in over 80 years
More articles by askcharlie
Print Article | Download PDF | 11 views | Oct 07 2008
|
|
